Product Description
CPB522 is a 1+1 bivalent bispecific structured after Tobemstomig but engineered to simultaneously target mouse programmed cell death protein 1 (PD-1, CD279) and mouse lymphocyte-activation gene 3 (LAG3). CPB522 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity and depletion of checkpoint-expressing effector T cells. This bispecific is designed to work by simultaneously blocking two non-redundant inhibitory pathways on exhausted T cells, thereby more effectively reversing dysfunction than targeting either PD-1 or LAG-3 alone. PD-1 is an inhibitory receptor on activated and chronically stimulated T cells whose engagement by PD-L1/PD-L2 dampens TCR signaling, reduces cytokine production, and promotes an exhausted phenotype in tumors. LAG-3 is a co-inhibitory receptor expressed on exhausted CD8 T cells, Tregs, and other lymphocytes, and binding to ligands such as MHC II contributes to reduced proliferation, cytokine secretion, and cytotoxic function especially in chronic antigen exposure and in the tumor microenvironment. PD-1 and LAG-3 are often co-expressed on highly exhausted, tumor-reactive tumor infiltrating lymphocytes (TILs). Bispecifics that concurrently bind both targets can concentrate functional activity on this subset, enhancing proximal TCR signaling and restoring effector function, effectively reactivating anti-tumor activity while potentially sparing less-activated peripheral T cells.
* VAT and shipping costs not included. Errors and price changes excepted
